Overview

• Researchers at PSI and Bern University Hospital have confirmed terbium-161 kills CD30-positive lymphoma cells up to 43 times more effectively than lutetium-177 in lab tests.
• Terbium-161 emits conversion and Auger electrons to deliver targeted radiation within micrometre distances, minimizing damage to healthy organs.
• Preclinical studies in mice showed treated subjects survived twice as long as those given lutetium-177 and some achieved complete cancer remission.
• The isotope’s 6.9-day half-life allows manufacturing at PSI and transport to clinical sites with minimal loss of activity.
• Follow-on funding from Innosuisse will support optimization and regulatory groundwork for upcoming human clinical trials.